EUVIMEDEUVIMED entdecken
Crossref

On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries

Blythe Adamson iD, Huub C Gelderblom iD, Maurine D Miner iD, Lawrence Corey iD

Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)

DOI: 10.57264/cer-2026-0120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Blythe Adamson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Economics, New York, NY 10025, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Antibodies, Monoclonal, Developed Countries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To quantify the market opportunity and economic impact of broadly neutralizing monoclonal antibodies (bnAbs) as a novel HIV prevention modality in high-income countries. Materials & methods: Using a decision-tree and revenue model applied to an eligible US population of 1299,708 individuals and projecting to 2040, bnAbs are estimated to capture 1 in 8 PrEP users (12.5% of PrEP users, 95% credible interval 7.3% to 21.1%, equivalent to 8.0% of the prevention-eligible population) following assumed US FDA approval in 2030. All estimates are scenario based and conditional on assumed pricing, uptake and behavior; none are observed outcomes. Critically, roughly half of projected bnAb users, nearly 52,000 individuals, would not otherwise use any biomedical HIV prevention, representing a net expansion of PrEP users (95% credible interval: 21,859–95,581). US manufacturer revenue totaled $12.0 billion discounted at 3% per year to 2030 (95% credible interval $6.2 billion to $21.9 billion), equivalent to $14.5 billion undiscounted, over the 11 years from approval to 2040. Total US payer spending rose 3.6% ($463.6 million annually), though the credible interval crosses zero, and the mean cost per prevention user decreased provided bnAbs are priced at the modeled list price of $14,000 per year, below existing injectable PrEP options.

Conclusion

Under the assumptions modeled here, bnAbs could reach roughly one in eight PrEP users in high-income countries, about half of them people not otherwise using biomedical prevention. Whether this translates into an attractive commercial opportunity, and whether per-user prevention costs fall or rise, depends principally on how bnAbs are priced relative to long-acting injectable PrEP. These are projections conditional on assumed efficacy, pricing and adoption behavior, not observed outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisAntibodies, MonoclonalDeveloped CountriesBroadly Neutralizing AntibodiesHumansUnited StatesCost-Benefit AnalysisDecision Trees

Stichwörter der Autor:innen

HIV preventionPrEPbnAbsbroadly neutralizing monoclonal antibodieshigh-income countriespre-exposure prophylaxis

Substanzen

Antibodies, MonoclonalBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Infectious Economics, New York, NY 10025, USA.
  • Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

ORCID-Profile: Blythe Adamson, Huub C Gelderblom, Maurine D Miner, Lawrence Corey

Zitieren

APA

Adamson, B., Gelderblom, H. C., Miner, M. D., & Corey, L. (2026). On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0120

Vancouver

Adamson B, Gelderblom HC, Miner MD, Corey L. On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0120

BibTeX
@article{Adamson2026,
  author = {Adamson, Blythe and Gelderblom, Huub C and Miner, Maurine D and Corey, Lawrence},
  title = {On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.57264/cer-2026-0120}
}
Kostenlos starten →